AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
Jun 29, 2012
29977_dirs_2012-06-29_c54d3c77-d7bd-4dcf-91b3-24f13d9fb26e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-06-27
Reporting Person: YANCOPOULOS GEORGE (Director, EVP CSO Pres REGN Res Lab)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-06-27 | Common Stock | A | 500000.0 | $0.0 | Acquired | 1333041.0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 5534.0 | Indirect |
Footnotes
F1: Subject to the terms of the award agreement, this award of Restricted Stock under the Second Amended and Restated 2000 Long-Term Incentive Plan vests in its entirety on December 17, 2017.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3